Jesse’s Journey grants $1M toward the launch of a clinical trial for Duchenne muscular dystrophy in Canada

Rockville MD, 11 June 2020

Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in More >

More >

ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys

Rockville MD, 2 June 2020

Vamorolone is a first-in-class daily oral drug being developed to improve muscle function in Duchenne muscular dystrophy. Vamorolone has multiple mechanisms of action shown by published pre-clinical studies, including potent anti-inflammatory  More >

More >